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Abstract
Arterial hypertension is an independent predictor of acute myocardial infarction. Nowadays, plasma levels of fibronectin and
matrix metalloproteinase 9 are the markers of left ventricular remodeling.
The objective of the research was to investigate potential antifibrotic effects of Quercetin in patients with acute myocardial
infarction and arterial hypertension.
Material and methods. 130 patients with myocardial infarction (63 individuals with concomitant arterial hypertension and 67
individuals without it) were observed. All the patients were divided into groups of basic treatment and additional prescription
of Quercetin. Transthoracic echocardiogram was used. To evaluate plasma level of fibronectin and matrix metalloproteinase 9
the ELISA method was applied.
Results. In all the patients, a significant decrease in fibronectin plasma levels was observed since the 28th day of treatment;
however, it was more significant in group of additional prescription of Quercetin. Revascularization and pharmacological
management of myocardial infarction resulted in the reduction in matrix metalloproteinase 9 plasma levels in all the patients
since the 7th day of treatment; however, it was more significant in group of additional prescription of Quercetin.
Conclusions. Quercetin possesses potential antifibrotic properties causing a reduction in plasma levels of fibronectin and
matrix metalloproteinase 9 in patients with myocardial infarction and concomitant arterial hypertension.
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Problem statement and analysis of the
recent research
Arterial hypertension (AH) is a major cardiovascular risk fac-
tor affecting approximately 30–45% of the general population
worldwide [1]. Hypertension is associated with an increased
incidence of other risk factors directly contributing to the
development and progression of atherosclerotic disease [2].
Accordingly, patients with myocardial infarction (MI) and a
history of AH are known to be older and to have a higher rate
of comorbidities and more extensive atherosclerotic disease
than patients with MI and without hypertension [3]. Several
studies demonstrated that patients with MI and antecedent AH
are at increased risk of adverse cardiovascular events, such
as heart failure, recurrent MI or even death [4, 5]. Thus, in
substudy of the AIDA-STEMI trial, antecedent hypertension
was associated with a significantly increased baseline risk
profile (advanced age, higher body mass index, higher inci-
dence of diabetes mellitus, hypercholesterolemia, previous
angioplasty and multivessel disease, p<0.001 for all). Major
adverse cardiovascular events (MACE) were more frequent
in patients with hypertension as compared to patients without
hypertension (45 (8%) vs. 8 (3%), p<0.01). AH remained an
independent predictor of MACE after multivariate adjustment
(hazard ratio 3.42 (confidence interval 1.45-8.08), p<0.01)
with no significant difference in the area at risk, infarct size,
myocardial salvage index, extent of microvascular obstruction,
and left ventricular ejection fraction [6].
Ischemic cell death during MI leads to a multiphase repar-
ative response in which the damaged tissue is replaced with a
fibrotic scar produced by fibroblasts and myofibroblasts. This
also induces geometrical, biomechanical, and biochemical
changes in the uninjured ventricular wall eliciting a reactive
remodeling process that includes interstitial and perivascular
fibrosis [7]. Although the initial reparative fibrosis is crucial
for preventing rupture of the ventricular wall, an exagger-
ated fibrotic response and reactive fibrosis outside the injured
area are detrimental as they lead to progressive impairment of
cardiac function and eventually to heart failure [7].
The extracellular matrix (ECM) is a dynamic microenvi-
ronment and a major contributor to the adverse ventricular
remodelling that follows MI, via activation of both direct pro-
fibrotic pathways and matrix metalloproteinases (MMPs) and
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fibronectin (Fn) that enhance collagenase activity. Reactive
fibrosis, i.e. deposition of ECM materials remote from the
region of MI is clearly detrimental to ventricular function and
contributory to adverse outcomes of post-MI [8]. Therefore,
reversal of this process is an important therapeutic target in
post-MI management.
Quercetin as one of flavonoids has long been acknowl-
edged for its unique antioxidant properties; it possesses other
activities that may be relevant to heart ischemia–reperfusion.
It may prevent production of oxidants (e.g. by inhibition of
xanthine oxidase and chelation of transition metals), inhibit
oxidants from attacking cellular targets (e.g. by electron dona-
tion and scavenging activities), block propagation of oxidative
reactions (by chain-breaking antioxidant activity), and rein-
force cellular antioxidant capacity (through sparing effects
on other antioxidants and inducing expression of endogenous
antioxidants) [9]. Flavonoids also possess anti-inflammatory
and anti-platelet aggregation effects through inhibiting rele-
vant enzymes and signaling pathways, resulting ultimately in
lower oxidant production and better re-establishment of blood
in the ischemic zone [9].
The objective of the research was to investigate potential
antifibrotic effects of Quercetin in patients with acute MI and
AH.
1. Materials and methods
130 patients with ST-elevation MI were involved in the study.
There were 82 (63.07%) males and 48 (36.93%) females. The
average age was (64.68±12.59) years. All the patients were
divided into 2 groups: 63 persons with AH and 67 persons
without AH. Each group was divided into 2 subgroups ac-
cording to the therapeutic scheme: subgroup IA included 33
patients receiving basic treatment; subgroup IB included 34
patients who additionally received Quercetin (parenterally
within the first 5 days, and, then, orally at a dose of 40 mg
twice a day); subgroup IIA involved 33 patients receiving
basic treatment; subgroup IIB comprised 30 patients who
additionally received Quercetin at similar doses.
Transthoracal echocardiography was performed and the
types of myocardial remodeling were calculated according to
the recommendations of the American Society of Echocardio-
graphy (ASE) and the European Association of Echocardiog-
raphy [10].
Plasma levels of Fn and matrix metalloproteinase 9 (MMP-
9) were detected using the ELISA method.
The investigation was performed before, on the 7th and
the 28th days of treatment as well as 3 months after treatment.
The study was performed in accordance with the Helsinki
Declaration and Good Clinical Practice Guidelines. The study
was approved by the local ethics committee and written in-
formed consent was obtained from all the patients.
Categorical variables are presented as percentages, whereas
normally distributed continuous variables are presented as the
mean (M) and the standard error of the mean (m) and non-
normally distributed ones are presented as the median and the
interquartile range (Me (IQR)). Categorical variables were
compared by the χ2 test and continuous variables were com-
pared using the t-test or the Mann-Whitney U test. A p value
of <0.05 was considered statistically significant. All tests
were 2-sided. The analyses were performed using Statistica
software (version 12.0).
2. Results and discussion
In all the patients, a significant decrease in Fn plasma levels
was observed since the 28th day of treatment; however, it
was more significant in group of additional prescription of
Quercetin (Table 1). In subgroup IA, this parameter decreased
by 21.12% (p<0.01), and by 43.35% (p<0.001) at the end
of the study. In patients of subgroup IB, Fn plasma level
decreased by 33.57% (p<0.01) since the 28th day of treatment
and by 51.70% (p<0.01) at the end of the 3rd month being
15.15% and 14.1% higher (p<0.05) than in patients receiving
basic treatment.
Similar dynamic was observed in patients with MI and
AH. In patients of subgroup IIA, Fn plasma level decreased
by 20.79% (p<0.01) on the 28th day of study, and by 39.13%
(p<0.001) at the end of the observation period. We noted
slower dynamics of this parameter in patients with AH (∆=9.72%,
p<0.05). Additional prescription of Quercetin resulted in
more intensive reduction in Fn plasma level: by 25.34%
(p<0.01) on the 28th day of treatment and by 47.99% (p<0.01)
at the end of study being 9.72% and 8.3% higher (p<0.05)
than in patients receiving basic treatment.
Revascularization and pharmacological management of
MI resulted in the reduction in MMP-9 plasma levels in all the
patients since the 7th day of treatment; however, it was more
significant in group of additional prescription of Quercetin
(Table 1). In subgroup IA, this parameter decreased by 11.59%
(p<0.05) on the 7th day of treatment, by17.48% (p<0.01) on
the 28th day and by 24.63% (p<0.001) on the 3rd month.
In subgroup IB, it decreased by 14.52% (p<0.05), 34.57%
(p<0.01) and 37.31% (p<0.001), respectively, being 19.03%
and 15.04% higher (p<0.05) than in patients receiving basic
treatment (since the 28th day until the 3rd month).
During the observation periods, in patients with concomi-
tant AH, plasma levels of MMP-9 decreased by 12.69% (p<0.05),
20.77% (p<0.01) and 24.29% (p<0.001), respectively. In
group of additional prescription of Quercetin, this parameter
decreased by 15.19% (p<0.05), 34.43% (p<0.01) and 38.05%
(p<0.001), respectively.
According to last clinical trials, an ideal therapy for MI-
induced cardiac injury would combine the inhibition of reac-
tive fibrosis (and other remodeling processes) in non-infarcted
areas with the induction of the regeneration of the infarcted
myocardium for example, by direct reprogramming of fibrob-
lasts to cardiomyocytes. A more detailed understanding of the
gene programmes, signaling cascades, and cellular metabolic
routes deciding between regeneration in neonatal rodents or
scarring and remodeling in adults is, however, critical for the
development of such therapeutics [7].
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Table 1. Dynamics of fibrosis markers in patients with MI
Parameter Patients without AH, n=67 Patients with AH, n=63IA, n=33 IB, n=34 IIA, n=33 IIB, n=30
Fibronectin, mcg/ml
- before treatment 479.87±15.41 483.56±17.11 494.74±16.11 489.77±17.11
- on the 7th day 471.43±14.11 476.21±14.47 483.47±17.14 481.57±14.54
- on the 28th day 378.54±16.14oo 321.21±13.47ooo* 391.87±15.47oo 365.68±13.74oo*#
- on the 3rd month 271.87±15.61ooo 233.56±12.87ooo* 301.14±13.47ooo# 254.71±19.11ooo*
MMP-9, ng/ml
- before treatment 91.78±6.98 93.74±5.87 97.89±5.79 98.74±6.32
- on the 7th day 81.14±4.23o 80.13±6.11o 85.47±4.78o 83.74±5.11o
- on the 28th day 75.74±5.14oo 61.33±5.77oo* 77.56±6.11o 64.74±4.98oo*
- on the 3rd month 69.17±7.11oo 58.77±4.78ooo* 74.11±5.11oo 61.17±5.74ooo*
Notes.
1. Continuous variables are presented as the mean (M) and the standard error of the mean (m);
2. Difference between parameters: o p<0,05; oo p<0,01; ooo p<0,001 – in one group compared to preliminary data;
3. Difference between parameters: # p<0,05 depending on concomitant AH;
4. Difference between parameters: * p<0,05; ** p<0,01; *** p<0,001 – compared to group of basic treatment
Conclusions
Quercetin possesses potential antifibrotic properties causing a
reduction in plasma levels of Fn and MMP-9 in patients with
MI and concomitant AH.
Perspectives for further research
Prospects for further research include the study of different
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